With this Phase III, two-protocol program, the sponsor hoped to extend the label of its antidepressant drug to children and adolescents.
It’s no surprise that doctors enthuse about the new CGRP class of migraine prevention drugs currently under development. More than 36 million Americans suffer from migraine attacks, and of these, about 4 million have chronic migraine.
Acurian consistently receives high marks for delivering the number of patients needed to close an enrollment gap. However, the quality of our patients is just as important. That’s why we centrally pre-screen every respondent using comprehensive, IRB-approved pre-screeners to confirm study eligibility. In fact, on average, only 10% of all respondents are referred to sites for further screening and processing.
With this phase IV, two-protocol study, the sponsor was hoping to demonstrate the superior efficacy of its marketed product versus another competitive product among adolescents with attention-deficit/ hyperactivity disorder (ADHD).
We’re the nerve center for CNS trials of every type.
Acurian’s extensive trial experience with autism to Alzheimer’s, MDD to Generalized Anxiety Disorder, and other CNS indications, stems from our sensible and sensitive approach to enrolling the patient you need, for as long as you need them.
Acurian is the leader in the patient recruitment and retention industry.
Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical and biotech companies representing over 4,500 research sites.